CION Ameerpet
Breast cancer found early is one of the most treatable of all cancers — at CION, 1-year survival for breast cancer is 96.9% versus a national average of 85.4%.* Screening is simply checking a healthy breast for cancer before any lump or symptom appears, so it can be caught at its smallest, most curable stage. But the right test and the right age differ from woman to woman: an average-risk woman, a woman with a family history, and a woman with dense breasts each need a different plan. This guide explains when to start, which test you need, and what happens if screening finds something — and at CION, a woman-headed, tumor-board-led team sets up exactly the screening you need, with no rushed decisions and no unnecessary tests.
The single biggest factor in surviving breast cancer is how early it is found. A screening test can detect a tumour while it is still tiny and confined to the breast — often years before it grows large enough to feel as a lump. Caught at this stage, treatment is usually simpler, gentler and far more successful: breast cancer found at stage 0 or stage 1 has close to 100% five-year survival, while cancer found late, after it has spread, is much harder to treat.
This matters especially in India. Breast cancer is now the most common cancer in Indian women, and it tends to appear about a decade younger than in the West. Yet most cases here are still detected late, when a woman finally notices a lump herself. Regular screening flips that pattern — it is designed to find cancer before symptoms, which is exactly why outcomes are so much better. At CION, breast cancer 1-year survival is 96.9% compared with a national average of 85.4%,* a gap built largely on earlier detection and team-led care.
Screening detects cancers a few millimetres across — often before a lump can be felt — when breast-conserving surgery and milder treatment are far more likely to succeed.
Stage 0-1 breast cancer has near 100% 5-year survival; survival falls sharply once cancer spreads to lymph nodes or beyond, so finding it early genuinely changes the outcome.
Breast cancer is the leading cancer among Indian women and often strikes younger than in the West — yet most cases are still caught late, which screening is designed to prevent.
CION's 1-year breast cancer survival of 96.9% against an 85.4% national average* reflects what earlier detection plus tumor-board-led care can achieve.
Breast cancer is now the most common cancer in Indian women, and on average it appears about a decade younger than in Western countries. Yet a majority of Indian cases are still detected at an advanced stage, because they are found only when a woman notices a lump herself rather than through screening. Screening is designed to find cancer before any symptom appears — which is exactly why it improves survival so dramatically. Source: ICMR National Cancer Registry Programme (NCRP).
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
There is no single age that fits everyone. The right schedule depends on whether you are at average risk or high risk, and the major guidelines broadly agree on the framework below.
The Indian Breast Imaging Society, ICMR, the American College of Radiology and the American Cancer Society broadly agree on one idea: average-risk women begin in their 40s, while high-risk women start earlier and add MRI. One firm rule applies to everyone — screening mammography is not started before age 25, whatever the risk, because young breast tissue is too dense to read reliably. The guidance below is a starting point, not a prescription; your own plan should be set by a specialist who knows your family history, breast density and personal risk. At CION, that assessment is part of your free first consultation.
Monthly breast self-awareness from about age 25, plus a clinical breast examination by a doctor every 1-3 years. Routine mammography is not usually advised at this age because dense young breast tissue makes it hard to read.
Most Indian and American guidelines advise starting annual (or at least every-2-year) mammography from age 40, together with a yearly clinical breast examination. This is the age at which the benefit of mammography clearly outweighs the small downsides for average-risk women.
There is universal agreement that women aged 50-69 benefit most from regular mammography — annual or every two years depending on breast density and the guideline followed. Continue clinical breast examination yearly alongside it.
Indian guidance commonly advises mammography up to about age 70; beyond that, screening is continued as long as you are in good general health and would be fit for treatment if cancer were found. This is an individual decision with your doctor.
Women with a strong family history, a known BRCA1/BRCA2 mutation, prior chest radiation, or a calculated lifetime risk of about 20-25% or more are screened from their 30s — annual mammography plus annual breast MRI, often from age 30 (MRI from 25-30 in the highest-risk genetic syndromes).
Screening is not one test but a toolkit, and the right tool depends on your age, breast density and risk.
A mammogram is the backbone of screening for most women. Ultrasound and MRI are added when a mammogram alone isn't enough — typically for younger women, dense breasts, or high-risk women. Understanding what each test does, and when it is used, helps you have a more confident conversation with your specialist rather than simply accepting whatever package a lab offers. A common, costly mistake is choosing a test by price alone: the cheapest scan is not the right one if it can't see your breast tissue clearly. At CION, the test is matched to you — and where a scan is needed, diagnostics are available at up to 50% discount with same-day, expert-reviewed reports.
A low-dose breast X-ray taken in two views, and the standard screening test for women 40 and over. It can show tiny calcium specks and small masses long before they can be felt. Digital and 3D (tomosynthesis) mammograms read dense breasts better and lower the chance of being called back. In Hyderabad a screening mammogram typically costs around 1,500-3,500 (3D mammography more).
Uses sound waves, no radiation, and is excellent at telling a harmless fluid cyst from a solid lump. It is the preferred first imaging test for women under about 35-40 whose breast tissue is too dense for a clear mammogram, and is frequently added to mammography in dense breasts to catch cancers a mammogram can miss.
A magnetic scan (no radiation) that is the most sensitive way to detect breast cancer, picking up cancers that mammography and ultrasound can miss. Because it can also flag harmless areas, it is reserved for high-risk women — a known BRCA mutation, a strong family history, or prior chest radiation — usually added to an annual mammogram from the 30s.
A trained doctor examines both breasts and the underarm lymph nodes by hand, looking and feeling for lumps, skin or nipple changes. It is a simple, low-cost layer recommended yearly from age 40 (and every 1-3 years from the 20s-30s) — useful alongside imaging, especially where access to mammography is limited.
A mammogram can miss cancers in dense breasts; an ultrasound may not show the tiny calcifications a mammogram catches. Picking a scan on price alone can give false reassurance. The right combination — decided by a specialist for your age and density — is what actually protects you, and at CION diagnostics come with up to 50% discounts and same-day expert-reviewed reports.
Imaging is the engine of screening, but two simpler habits sit alongside it — and they matter most for women too young for routine mammography.
Breast self-awareness means knowing how your own breasts normally look and feel, so you notice a change quickly. A clinical breast examination (CBE) is the same idea performed by a trained doctor. Neither replaces a mammogram for women 40 and over, but together they are an important front line — many Indian breast cancers are still first noticed by the woman herself. Be clear about their limits, though: self-examination cannot reliably find the tiny, early cancers a mammogram detects, so it is a complement to screening, never a substitute. The goal is not anxious monthly hunting for lumps, but simply knowing your normal and acting promptly on any change.
Breast self-awareness from about age 20-25 means learning how your breasts usually look and feel through the month, so any new or persistent change stands out — rather than performing a tense, rigid examination.
Report a new lump in the breast or underarm, a change in size or shape, skin dimpling or puckering, nipple turning inward or discharge (especially blood-stained), and persistent redness, rash or pain in one area.
If you menstruate, check a few days after your period when breasts are least tender; after menopause, pick a fixed day each month. Look in a mirror with arms down then raised, then feel the whole breast and underarm in small circles.
A doctor examines both breasts and the lymph nodes by hand. Indian guidance suggests CBE every 1-3 years from the 20s-30s and yearly from 40 — a low-cost layer that is especially valuable where mammography access is limited.
Self-exam and CBE cannot find the millimetre-sized cancers a mammogram detects, so they do not replace screening for women 40 and over. Their job is to catch changes between scans — and to prompt younger women to see a specialist early.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Woman-led, tumor-board-reviewed care across 35+ centres in Telangana & AP, with same-day expert-reviewed reports. Call 1800-202-8726.
Standard screening is built for average-risk women. Two groups need a more intensive plan: women at high genetic or family risk, and women with dense breasts. They are not the same thing — a woman can be one, the other, or both — but each means a mammogram alone may not be enough.
A known BRCA1/BRCA2 (or other high-risk gene) mutation; a strong family history of breast or ovarian cancer, especially relatives diagnosed young or on both sides; prior chest/mantle radiation, particularly before age 30; or a lifetime risk of roughly 20-25% or more on a validated risk model such as the Tyrer-Cuzick or Gail score.
For high-risk women, guidelines recommend annual screening mammography plus annual breast MRI, typically starting around age 30 (MRI as early as 25-30 in the highest-risk genetic syndromes such as Li-Fraumeni). Where a relative was affected young, screening often begins about 10 years before that relative's age at diagnosis.
Breast density describes how much glandular and fibrous tissue you have versus fat; it is reported on your mammogram (BI-RADS categories C and D are 'dense'). It has nothing to do with how breasts feel and cannot be judged by touch — only a mammogram can tell you, and density tends to be higher in younger women.
Dense tissue appears white on a mammogram, and so do most tumours — so a cancer can hide in plain sight, lowering a mammogram's sensitivity. Dense breasts also carry a modestly higher cancer risk. For these women, adding ultrasound (and MRI in higher-risk cases) finds cancers that mammography alone would miss.
Whole-breast ultrasound is the most common add-on for women with dense breasts who are not high-risk enough to need MRI. It uses no radiation and detects additional cancers, though it does raise the chance of a benign call-back — a trade-off your specialist will weigh with you.
Being high-risk or having dense breasts does not mean every test, every year — it means the right combination, set deliberately. At CION the tumor board reviews high-risk and dense-breast cases and tailors the schedule, so you are neither under-screened nor over-tested, with diagnostics at up to 50% discount.
This is the part that frightens women most — and it is where most worry turns out to be unnecessary. An abnormal screening result very rarely means cancer.
Out of every 100 women screened, roughly 10 are called back for more pictures, only about 2 go on to a biopsy, and even then most biopsies prove harmless. A call-back is not a diagnosis; it simply means a closer look is needed. If your mammogram shows something unclear, the next steps follow a calm, well-worn path that doctors call triple assessment — combining examination, more detailed imaging, and (only if needed) a biopsy. Knowing this sequence in advance takes much of the fear out of a call-back. At CION every such case is reviewed by the tumor board, so any decision about a biopsy or treatment is made by a team, not a single doctor.
The commonest next step is simply more pictures — extra mammogram views or a targeted ultrasound — to look more closely at the area. Most call-backs end here, with an all-clear or a finding that is clearly harmless, such as a cyst.
If an area still looks uncertain, doctors combine three things — a clinical examination, detailed imaging (mammogram and/or ultrasound, sometimes MRI), and a needle biopsy — to reach a confident answer. This combined approach is the gold standard and is far more accurate than any one test.
Only a biopsy — a thin needle taking a small tissue sample, usually under local anaesthetic — can confirm whether a finding is cancer. Most biopsies turn out benign. If it is cancer, the same sample tells doctors the type and characteristics needed to plan the right treatment.
Per 100 women screened, about 90 have no concern, around 10 are recalled, roughly 2 need short-interval follow-up, and about 2 need a biopsy — and most biopsies are not cancer. A call-back is a precaution, not a verdict.
If cancer is confirmed, you are not handed a single opinion. At CION every case goes to the tumor board — medical, surgical and radiation oncologists together — who agree a plan in a 45-minute consultation, with transparent costs and no unnecessary tests. Decisions for healing, not billing.
Knowing the guidelines is one thing; getting the right screening, conveniently and affordably, is another. CION makes that simple. With 35+ centres across Telangana and AP and PET-CT and diagnostic locations across Hyderabad — Jubilee Hills, Banjara Hills, Punjagutta, Himayatnagar and Narayanaguda — quality breast screening is close to home, with same-day, expert-reviewed reports.
What sets CION apart is not just access but judgement. As a woman-headed, tumor-board-led organisation, we begin with a free 45-minute consultation to assess your real risk and decide which test you actually need — rather than selling a one-size-fits-all package. The pathway below is how a typical screening visit works.
A specialist reviews your age, family history and breast density, examines you if needed, and explains in plain language exactly which screening test you need — and which you don't. Free for all cancer patients, no pressure, no unnecessary tests.
Mammogram, ultrasound or MRI as appropriate, across centres in Jubilee Hills, Banjara Hills, Punjagutta, Himayatnagar and Narayanaguda — with up to 50% discounts on diagnostics and same-day, expert-reviewed reports.
Any abnormal result is reviewed by the full tumor board — medical, surgical and radiation oncologists together — so a call-back or biopsy decision is made by a team, not one doctor, with transparent costs throughout.
You leave with a clear schedule for your future screening — the right test at the right interval for your risk — plus access to nutrition and psycho-oncology support, all backed by 150+ years of combined experience and a 4.8/5 Google rating.
*1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP). CION figures are network outcomes; national figures are population averages and do not predict an individual's result.
Hear from women whose breast cancer was found early at CION — and the gentler treatment and outcomes that early detection made possible.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.For women at average risk, most Indian and international guidelines advise starting annual mammography at age 40, with a yearly clinical breast examination. Before 40, the focus is on breast self-awareness and a clinical breast examination every 1-3 years, since dense young breast tissue makes mammograms hard to read. Women aged 50-69 benefit most and should not skip screening. If you are at high risk — a strong family history, a known BRCA mutation, or prior chest radiation — you should start earlier, usually in your 30s, and add an annual breast MRI. One rule applies to everyone: screening mammography is not started before age 25. A specialist can confirm the right starting age for your personal risk.
For average-risk women aged 40 and over, guidelines recommend a mammogram either every year or every two years, depending on your breast density and the guideline followed. Annual screening detects cancers slightly earlier; every-two-year screening means fewer call-backs. Women with dense breasts or any extra risk are usually advised to screen annually. High-risk women have an annual mammogram plus an annual breast MRI. The best interval for you depends on your age, breast density, family history and previous results — which is exactly what a screening consultation is for. At CION, we set your interval individually rather than applying a single rule to everyone.
A mammogram is a low-dose breast X-ray and the standard screening test for women 40 and over; it is excellent at spotting tiny calcium specks and small masses. A breast ultrasound uses sound waves and no radiation — it is best for younger women and dense breasts, and tells a harmless cyst from a solid lump. A breast MRI is the most sensitive test of all, used mainly for high-risk women (such as those with a BRCA mutation) added to their mammogram. They are not interchangeable: the right test depends on your age, breast density and risk. A specialist matches the test to you rather than selecting by price.
Costs vary by test and centre. In Hyderabad a clinical breast examination is roughly 300-800 (sometimes free at awareness camps), a 2D digital mammogram around 1,500-3,500, a 3D mammogram around 3,000-6,000, a breast ultrasound around 1,000-3,000, and a breast MRI from about 7,000 upwards. Bundled screening packages combining a mammogram with a consultation are commonly available. Choosing by price alone can be a false economy — the cheapest scan is not the right one if it cannot read your breast tissue clearly. At CION, diagnostics are available at up to 50% discount, and your first consultation to decide which test you actually need is free. Call 1800-202-8726 for a current estimate.
Often, yes. Dense breasts have more glandular and fibrous tissue, which matters for two reasons. First, dense tissue slightly raises your breast cancer risk. Second, dense tissue appears white on a mammogram and so do tumours, so a cancer can hide and be missed. For this reason, women with dense breasts are frequently advised to add a supplemental breast ultrasound to their mammogram, and high-risk dense-breast women may need MRI. Importantly, you cannot tell breast density by touch — only a mammogram report (graded as BI-RADS C or D) can tell you. If your report says your breasts are dense, ask a specialist whether supplemental imaging is right for you.
No — they do different jobs and one cannot replace the other. Breast self-awareness means knowing how your breasts normally look and feel so you notice a change quickly, and it is valuable, especially for younger women. But self-examination cannot reliably find the tiny, millimetre-sized cancers that a mammogram detects years before they can be felt. By the time a cancer is large enough to feel as a lump, it is at a later stage than one found by screening. So self-exam is an important complement that catches changes between scans, but for women 40 and over it does not replace regular mammography. Use both: know your normal, and keep your screening appointments.
Almost certainly not. A call-back is very common and is not a diagnosis — it simply means the radiologist wants a closer look at one area. Out of every 100 women screened, around 10 are recalled for more pictures, but only about 2 go on to a biopsy, and most biopsies turn out to be harmless. A call-back usually means extra mammogram views or a targeted ultrasound, which most often shows something clearly benign such as a cyst or normal overlapping tissue. Only if an area still looks uncertain is a biopsy suggested. Try not to panic: the system is designed to be cautious, and the great majority of recalls end with reassuring news.
You move onto a calm, step-by-step pathway, not straight to treatment. First, you are called back for more detailed imaging — extra mammogram views or an ultrasound. If anything still looks uncertain, doctors use triple assessment: a clinical examination, detailed imaging, and a needle biopsy, combined for an accurate answer. Only a biopsy can confirm whether a finding is cancer, and most biopsies are benign. If cancer is confirmed, the biopsy also reveals the type and characteristics needed to plan treatment. At CION, every such case is reviewed by the tumor board — medical, surgical and radiation oncologists together — so any decision is made by a team, in a 45-minute consultation, with transparent costs.
Yes. CION offers a free first consultation for all cancer patients and women planning their screening. It is a full 45-minute session in which a specialist reviews your age, family history and breast density, examines you if needed, and explains exactly which screening test you need — and which you don't — in plain language. If imaging is needed, diagnostics are available at up to 50% discount with same-day, expert-reviewed reports, across centres in Jubilee Hills, Banjara Hills, Punjagutta, Himayatnagar and Narayanaguda. As a woman-headed, tumor-board-led organisation, we make decisions for healing, not billing — no unnecessary tests. You can book on 1800-202-8726 or request a callback through the form on this page.